APA

Arnould L., Arveux P., Couturier J., Gelly-Marty M., Loustalot C., Ettore F., Sagan C., Antoine M., Penault-Llorca F., Vasseur B., Fumoleau P. & Coudert B. P. (20080122). Pathologic complete response to trastuzumab-based neoadjuvant therapy is related to the level of HER-2 amplification. : Clinical cancer research : an official journal of the American Association for Cancer Research.

Chicago

Arnould Laurent, Arveux Patrick, Couturier Jerome, Gelly-Marty Marion, Loustalot Catherine, Ettore Francette, Sagan Christine, Antoine Martine, Penault-Llorca Frederique, Vasseur Berangere, Fumoleau Pierre and Coudert Bruno P. 20080122. Pathologic complete response to trastuzumab-based neoadjuvant therapy is related to the level of HER-2 amplification. : Clinical cancer research : an official journal of the American Association for Cancer Research.

Harvard

Arnould L., Arveux P., Couturier J., Gelly-Marty M., Loustalot C., Ettore F., Sagan C., Antoine M., Penault-Llorca F., Vasseur B., Fumoleau P. and Coudert B. P. (20080122). Pathologic complete response to trastuzumab-based neoadjuvant therapy is related to the level of HER-2 amplification. : Clinical cancer research : an official journal of the American Association for Cancer Research.

MLA

Arnould Laurent, Arveux Patrick, Couturier Jerome, Gelly-Marty Marion, Loustalot Catherine, Ettore Francette, Sagan Christine, Antoine Martine, Penault-Llorca Frederique, Vasseur Berangere, Fumoleau Pierre and Coudert Bruno P. Pathologic complete response to trastuzumab-based neoadjuvant therapy is related to the level of HER-2 amplification. : Clinical cancer research : an official journal of the American Association for Cancer Research. 20080122.